Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2018-12-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/antiangiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancer |
| id |
doaj-1fc5bdf633104df1a16c915a36c7ca42 |
|---|---|
| record_format |
Article |
| spelling |
doaj-1fc5bdf633104df1a16c915a36c7ca422020-11-24T21:33:17ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982018-12-0171910.7573/dic.212558Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinationsMarisa C LiuKrishnansu S TewariOver the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.https://www.drugsincontext.com/antiangiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancerbevacizumabcheckpoint inhibitorchemotherapyovarian cancerPARP inhibitor |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Marisa C Liu Krishnansu S Tewari |
| spellingShingle |
Marisa C Liu Krishnansu S Tewari Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations Drugs in Context bevacizumab checkpoint inhibitor chemotherapy ovarian cancer PARP inhibitor |
| author_facet |
Marisa C Liu Krishnansu S Tewari |
| author_sort |
Marisa C Liu |
| title |
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| title_short |
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| title_full |
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| title_fullStr |
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| title_full_unstemmed |
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| title_sort |
anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations |
| publisher |
BioExcel Publishing Ltd |
| series |
Drugs in Context |
| issn |
1740-4398 1740-4398 |
| publishDate |
2018-12-01 |
| description |
Over the last decade, new therapeutics in the form of anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition have offered new options for the treatment of ovarian cancer. This review summarizes studies related to these treatment modalities and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from. |
| topic |
bevacizumab checkpoint inhibitor chemotherapy ovarian cancer PARP inhibitor |
| url |
https://www.drugsincontext.com/antiangiogenesis-therapy-synthetic-lethality-and-checkpoint-inhibition-in-ovarian-cancer |
| work_keys_str_mv |
AT marisacliu antiangiogenesistherapysyntheticlethalityandcheckpointinhibitioninovariancancerstateofthescienceandnovelcombinations AT krishnansustewari antiangiogenesistherapysyntheticlethalityandcheckpointinhibitioninovariancancerstateofthescienceandnovelcombinations |
| _version_ |
1725953939877134336 |